
New life-extending lung cancer treatment approved by NICE
Thousands of lung cancer patients are now eligible for a new life-extending treatment through the Cancer Drugs Fund (CDF).
All NICE products on metastases. Includes any guidance, advice, NICE Pathways and quality standards.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Published guidance on this topic (94)
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (5)
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (2)
Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject.
Review the evidence across broad health and social care topics.
Reviews the clinical and cost-effectiveness of new treatments.
Review new diagnostic technologies for adoption in the NHS.
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Review the best available evidence for selected medicines.
Review the evidence and likely costs of medical devices and technologies.
Guidance, quality standards and advice being developed.
Technology appraisal guidance which has been proposed for development.
Thousands of lung cancer patients are now eligible for a new life-extending treatment through the Cancer Drugs Fund (CDF).
Hundreds of patients a year set to benefit from roll out of dye to all of England’s neurosurgical units
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 1 of 1 shared learning examples for this topic: